Peptide News Digest

Wegovy Pill Q1 721K Rx Ahead of Novo May 6, Drexel Peptide Q&A, Nature GLP-1 Umbrella Review, Pfizer Q1 + 20 Obesity Trials, Lilly MASLD, BriaCell Bria-OTS+

Novo's Wegovy pill hit 721K Q1 prescriptions ahead of May 6 print, Drexel Q&A on peptide safety, Nature GLP-1 umbrella review, Pfizer Q1 + 20 obesity trials.

10 stories · Covering industry, research, clinical-trials, regulatory

Editor's Note

May 5 set up Wednesday's Novo Nordisk Q1 print as the GLP-1 inflection point. Reuters reported the Wegovy pill booked roughly 721,000 US prescriptions in Q1 per IQVIA — about 450,000 of them on the cheapest 1.5 mg starter dose at $149/month — raising the question of whether prescription momentum can offset a falling-price headwind. Investors will be looking for whether Novo holds its February guidance of 5–13% sales and operating-profit decline at constant exchange rates. Beyond the pill war, Drexel's news desk ran a clinically grounded Q&A on peptide popularity and safety, and Nature Communications published an umbrella review of 123 meta-analyses spanning 464 GLP-1 receptor-agonist outcomes across 5,617 articles — the most comprehensive synthesis of the class to date, mapping benefits across endocrine, cardiovascular, renal, respiratory, and cognitive domains alongside the diabetic-retinopathy and ketoacidosis safety signals. Pfizer's April 29 Q1 print beat consensus and confirmed 20+ obesity trials in 2026 including 10 Phase 3 of PF'3944. Lilly's retatrutide MASLD Phase 3 (NCT06859268) is underway following 86% Phase 2 liver-fat reduction. AstraZeneca's ASCEND triple-mechanism Phase 2b is active. Beyond the GLP-1 frame, BriaCell's Bria-OTS+ next-gen peptide immunotherapy posted preclinical anti-cancer data at AACR 2026, BioVaxys provided further MVP-S validation in ovarian cancer May 1, Neurogan launched a 2% GHK-Cu body care, and Holt Law issued a California-specific regulatory alert on BPC-157 ahead of the July PCAC.

Industry

Reuters / US News (May 5): Novo Nordisk's Wegovy Pill Boom Faces Price War Test — IQVIA Tracks 721,000 US Q1 Prescriptions Ahead of Wednesday's Q1 Print

Reuters reported May 5 that Novo Nordisk's Wegovy pill posted roughly 721,000 US prescriptions in Q1 per IQVIA, beating analyst expectations on volume but raising margin questions: about 450,000 of those scripts were for the cheapest 1.5 mg starter dose at $149/month. Lilly's Foundayo approval in early April closed Novo's window as the only oral obesity pill, and Wegovy injection prices have fallen rapidly amid intensifying competition. The Danish company's market value has shed more than $400 billion from its 2024 peak. Wednesday's Q1 print (May 6, 7:30 CEST) is the test: investors are watching whether Novo holds February's guidance of a 5–13% sales and operating-profit decline at constant exchange rates, and whether direct-to-consumer NovoCare and the WW Med+ + GoodRx channels can offset price pressure.

#novo-nordisk #wegovy-pill #iqvia #q1-2026 #price-war #oral-glp-1
Industry

Drexel News Q&A (May 5): Why Are Peptides Becoming More Popular and Are They Safe?

Drexel University's news desk ran a May 5 Q&A on peptide popularity and safety, framed by the FDA's April Category 2 removals and the upcoming July 23–24 PCAC meeting on seven peptides for the 503A bulks list. The piece covers why peptides are surging — easier and cheaper synthesis since the 1980s genetic-engineering era, plus newer molecules like GLP-1 with broad therapeutic effects — and the safety gaps: pharmacy-to-pharmacy compounding variability, supply not keeping up with demand, and a gray-market problem that pushes patients to unverified online sources. The Q&A joins the AMA, AJMC, Pharmacy Times, MIT Technology Review, and the American Council on Science and Health pieces in the post-Category-2 consumer-education ecosystem.

#drexel #consumer-education #peptide-policy #category-2 #patient-safety #compounding
Research

Nature Communications Umbrella Review of GLP-1 Receptor Agonists: 123 Meta-Analyses Covering 464 Outcomes Across 5,617 Articles

A Nature Communications umbrella review by Kong, Zhao, Zhang and colleagues synthesized 123 meta-analyses covering 464 outcomes from 5,617 articles to comprehensively assess GLP-1 receptor agonist effectiveness and adverse events across diverse outcomes. Outcomes were grouped into seven categories: endocrine and metabolic, cardiovascular, cancer, renal, respiratory, mortality and adverse events, and other. The review documented improvements in metabolic, cardiovascular, renal, and respiratory outcomes plus cognitive function, with potential reductions in fracture risk and all-cause mortality in selected populations. Increased risks were observed for diabetic retinopathy, ketoacidosis, gastrointestinal events, and treatment discontinuation — useful evidence-summary input for ECO 2026 in Istanbul (May 12–15) and the prevention-trial proposal that 21 obesity-and-cancer experts will present there.

#glp-1 #umbrella-review #nature-communications #meta-analysis #diabetic-retinopathy #ketoacidosis
Industry

Pfizer Q1 2026 (April 29): Revenue $14.45B Beats Consensus on Strong Non-COVID Growth; 20+ Obesity Trials in 2026 Including 10 Phase 3 of PF'3944

Pfizer reported April 29 Q1 2026 revenue of $14.45 billion (vs. $13.92B consensus) and adjusted diluted EPS of $0.75 (vs. $0.72), with non-COVID operational revenue up 7%. The company reaffirmed 2026 guidance of $59.5–62.5B in revenue and $2.80–3.00 in adjusted EPS. On the obesity portfolio, Pfizer confirmed 20+ planned and ongoing studies across the diverse obesity pipeline acquired with Metsera, including 10 Phase 3 trials of PF'3944 (MET-097i) — the recently initiated Phase 3 VESPER-4 once-weekly study, the planned VESPER-5 in T2D, the planned VESPER-6 once-monthly maintenance study, and at least seven more. MET-233i, a monthly amylin analog, is in Phase 1 monotherapy and combination-with-PF'3944 development.

#pfizer #q1-2026-earnings #metsera #pf-3944 #vesper #obesity-pipeline
Clinical Trials

Eli Lilly Retatrutide MASLD Phase 3 Trial (NCT06859268) Underway, Phase 2 Showed 86% Liver-Fat Reduction at 48 Weeks

Eli Lilly's retatrutide MASLD Phase 3 trial (NCT06859268) is enrolling, building on Phase 2 data that reported up to 86% liver-fat reduction at 48 weeks with 93% of 12 mg patients reaching normal liver fat. The MASLD trial will measure histological resolution of steatohepatitis without worsening fibrosis — the endpoint that drives FDA approval in the indication. The trial sits within the broader TRIUMPH program of seven Phase 3 retatrutide readouts due in 2026, after TRIUMPH-4 (28.7% mean weight loss with knee-osteoarthritis pain reduction) and TRANSCEND T2D1 (A1c down 1.7–2.0 pts in T2D). MASLD remains a regulatory test for incretins after Boehringer's survodutide LIVERAGE Phase 3 program.

#retatrutide #eli-lilly #masld #mash #liver-fat #phase-3 #triumph
Clinical Trials

AstraZeneca ASCEND Triple-Mechanism Phase 2b Active: AZD9550 GLP-1/Glucagon Dual + AZD6234 Selective Amylin via CSPC Pharmaceuticals Collaboration

AstraZeneca's ASCEND program is active in Phase 2b, combining AZD9550 (GLP-1 + glucagon dual agonist) with AZD6234 (selective amylin analog) in a two-molecule triple-mechanism strategy aimed at fat-selective weight loss and organ protection. Individual assets are also in Phase 2. The combination reflects the February 2026 $1.2 billion CSPC Pharmaceuticals collaboration that brought both molecules into AstraZeneca's portfolio, alongside elecoglipron (AZD5004 / ECC5004), the small-molecule oral GLP-1 that posted 5.8% weight loss over four weeks in Phase 1b in China. AstraZeneca enters the next-gen obesity race later than Lilly, Novo, Roche, and Boehringer, but the triple-mechanism positioning targets the safety + organ-protection lane that competitors leave open.

#astrazeneca #ascend #azd9550 #azd6234 #amylin #glucagon-glp-1 #cspc-pharmaceuticals
Clinical Trials

BriaCell Bria-OTS+ Personalized Peptide Immunotherapy Shows Robust Anti-Cancer Activity in Preclinical Models, Heading to Clinic for Metastatic Breast and Prostate Cancer Late 2026

BriaCell announced April 21 preclinical results from its next-generation Bria-OTS+ personalized peptide immunotherapy at the AACR 2026 Annual Meeting. The platform pairs HLA-matched whole-cell allogeneic immunotherapy with peptide-mediated antigen targeting, building on the Bria-IMT clinical foundation in heavily pretreated metastatic breast cancer. Based on the preclinical anti-cancer activity, BriaCell plans to enter the clinic for metastatic breast cancer and prostate cancer indications later in 2026, with lung cancer and melanoma planned for 2027. The program adds to a peptide-immuno-oncology pipeline that includes the Bria-IMT Phase 3 and the company's six accepted ASCO 2026 presentations covering survival data, biomarkers, and quality-of-life endpoints.

#briacell #bria-ots-plus #personalized-immunotherapy #metastatic-breast-cancer #prostate-cancer #aacr-2026
Industry

Neurogan Health Launches 2% GHK-Cu Copper Peptide Body Care After 12-Week Clinical Trial Showing 32.8% Wrinkle Depth Reduction and 20–30% Skin Firmness Improvement

Neurogan Health expanded its product line with a topical 2% GHK-Cu copper peptide body care, supported by a 12-week clinical trial reporting 32.8% reduction in wrinkle depth and 20–30% improvement in skin firmness. The launch lands in a 2026 GHK-Cu market characterized by surging consumer interest — the peptide is the fastest-growing skincare ingredient by search volume, with patient interest spanning skin rejuvenation, hair loss, and systemic longevity. Topical GHK-Cu has the strongest evidence base among research peptides, going back decades on wound healing and collagen synthesis, and topical applications avoid the regulatory gray zone around the injectable formulation.

#neurogan-health #ghk-cu #copper-peptide #skincare #topical #anti-aging
Regulatory

Holt Law April Regulatory Alert: BPC-157 California Sherman Law Risk + Federal Pre-PCAC Compliance Reminders for Compounders

Holt Law's April update on BPC-157 reminded compounders and clinics that the FDA's Category 2 removal does not authorize compounding on its own — the seven-peptide PCAC meeting on July 23–24 is required first, followed by formal rulemaking. The alert flagged California-specific exposure: the state's Sherman Food, Drug and Cosmetic Law prohibits the sale or distribution of new drugs that have not received FDA or state approval, and prescribing or dispensing BPC-157 outside approved pathways could expose physicians to significant legal risks separate from federal enforcement. The piece complements the firm's January 2 critical-status alert and the broader 2026 state-by-state compounding-enforcement divergence between California (30+ Board of Pharmacy actions since 2023) and Texas (more permissive for licensed 503A operations).

#holt-law #bpc-157 #california #sherman-law #compounding-compliance #pcac
Clinical Trials

BioVaxys Presents Further MVP-S Validation Data (May 1): Robust Immune Response with Checkpoint Inhibitor + Low-Dose Cyclophosphamide in Recurrent Ovarian Cancer

BioVaxys presented additional validation data on May 1 supporting its MVP-S DPX-formulated five-peptide survivin vaccine in combination with checkpoint inhibitor pembrolizumab and low-dose cyclophosphamide in recurrent epithelial ovarian cancer. The new data extends the immune-response readout from the PESCO Phase 1B/2 program and reinforces the clinical case heading into the company's accepted ASCO 2026 abstract presentation (May 29–June 6, Chicago). MVP-S sits alongside Bicycle Therapeutics' Duravelo-2, BriaCell's Bria-IMT, Greenwich's GP2, Immutep's eftilagimod alfa, and Pfizer's 40+ oncology abstracts on the ASCO 2026 peptide-and-immuno-oncology slate.

#biovaxys #mvp-s #survivin #ovarian-cancer #checkpoint-inhibitor #cyclophosphamide #pesco